DVAX
NASDAQ
US
Dynavax Technologies Corporation - Common Stock
$15.50
+0.0 (+0.0%)
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.8B
ROE
-8.1%
Margin
-13.1%
D/E
48.87
Beta
1.03
52W
$9–$15
Wall Street Consensus
9 analysts · Apr 20262
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
77.8%
Buy Rating
Price Chart
Similar Stocks
SLNO
Soleno Therapeutics Inc
$2.5B
STOK
Stoke Therapeutics Inc
P/E 44.2
$1.8B
VRDN
Viridian Therapeutics Inc
$3.0B
CAPR
Capricor Therapeutics Inc
$1.6B
SION
Sionna Therapeutics Inc
$1.8B
VCEL
Vericel Corp
P/E 139.2
$1.8B
PVLA
Palvella Therapeutics Inc
$1.2B
ZYME
Zymeworks Inc
$2.0B
ANAB
AnaptysBio Inc
$1.3B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Sep 2025 | $0.13 | $0.21 | +$0.08 |
| Jun 2025 | $0.11 | $0.14 | +$0.03 |
| Mar 2025 | $0.04 | $0.01 | $-0.03 |
| Dec 2024 | $0.04 | $0.05 | +$0.01 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -9.2% | -9.2% | -9.2% | -9.2% | -8.1% | -8.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | 19.6% | -16.7% | -16.7% | -16.7% | -13.1% | -13.1% |
| Gross Margin | 85.3% | 82.8% | 82.8% | 82.8% | 83.2% | 83.2% |
| D/E Ratio | 52.77 | 52.77 | 52.77 | 52.77 | 48.87 | 48.87 |
| Current Ratio | 6.65 | 6.65 | 6.65 | 6.65 | 7.62 | 7.62 |
Key Ratios
ROA (TTM)
-4.6%
P/S (TTM)
5.46
P/B
2.8
EPS (TTM)
$-0.38
CF/Share
$0.44
Rev Growth 3Y
-14.2%
52W High
$15.49
52W Low
$9.20
$9.20
52-Week Range
$15.49
How does DVAX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
DVAX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
5.5
▼
57%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
2.8
▲
14%
above
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
DVAX profitability vs Biotechnology peers
ROE
-8.1%
▲
88%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-13.1%
▲
95%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
83.2%
▲
6%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-4.6%
▲
90%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
DVAX financial health vs Biotechnology peers
D/E ratio
48.9
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
7.6
▲
72%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.0
▲
6%
above
peers
(1.0)
vs Peers
vs Industry
Less volatile
DVAX fundamentals radar
DVAX
Peer median
Industry
DVAX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
DVAX vs peers: key metrics
Latest News
No related news yet